

# Table of Contents

<b>1. Gangliosides and Cancer: Introduction</b> <i>H. F. Oettgen</i> .....	1
<b>2. The Chemical Structures of Gangliosides</b> <i>H. Wiegandt</i> .....	5
<b>3. Bimodal Regulation of Cell Growth by Endogenous Gangliosides</b> <i>S. Spiegel</i> .....	17
<b>4. Biological Significance of Ecto Biosignal Transduction: Carbohydrate Recognition Coupled with Cell Surface Protein Phosphorylation</b> <i>Y. Nagai and S. Tsuji</i> .....	31
<b>5. Cyclic AMP Dependent Protein Kinase and Cyclic Nucleotide Phosphodiesterase Activities are Modulated by Gangliosides</b> <i>A. J. Yates, J. D. Walters, S. M. Stock, B. K. McIlroy, and J. D. Johnson</i> .	41
<b>6. General Concept of Tumor-associated Carbohydrate Antigens: Their Chemical, Physical, and Enzymatic Basis</b> <i>S. Hakomori</i> .....	57
<b>7. Cellular Expression of Glycolipids after Oncogene Transfection; Oncogene-type Specific Changes of Gangliosides in Rat 3Y1 Cells</b> <i>Y. Sanai and Y. Nagai</i> .....	69
<b>8. Diversity of Ganglioside Expression in Human Melanoma</b> <i>M. H. Ravindranath, T. Tsuchida, and R. F. Irie</i> .....	79
<b>9. A GM3 Epitope Expressed in Tumor Infiltrating Macrophages is Generated in Phagocytizing Monocytes in vitro</b> <i>F. Schriever, R. D. Dennis, B. Pallmann, G. Riethmuller, and J. P. Johnson</i> .....	93
<b>10. Monoclonal Antibody Detection of Ganglioside Expression in Human Neuroblastoma</b> <i>N.-K. V. Cheung, N. Usmani, C. Cordon-Cardo, A. N. Houghton, J. Biedler, and H. F. Oettgen</i> .....	103
<b>11. Gangliosides of Human Gliomas in vivo and in vitro</b> <i>P. Fredman</i> .....	109

<b>12. Exo-1, a Neutral Glycolipid of Human Epithelial Cells Expressed at Certain Stages of Spinous Cell Differentiation of Human Keratinocytes</b> <i>R. Klingel, K.-H. Meyer zum Büschenfelde, and W. Dippold</i> . . . . .	117
<b>13. Hepatoma-associated Gangliosides – Gangliosides with N-Acetylneuraminosyl(<math>\alpha</math>2–6)galactose Structure</b> <i>T. Taki, K. Ishii, and A. Myoga</i> . . . . .	127
<b>14. Analysis of Tumor-associated Gangliosides in Acute Leukemic Lymphoblasts Utilizing Anti-GD3 and Anti-GM3 Monoclonal Antibodies</b> <i>W. D. Merritt, M.-B. Szein, and G. H. Reaman</i> . . . . .	137
<b>15. Mouse Monoclonal Antibodies to Ganglioside GD2: Characterization of the Fine Structural Specificities</b> <i>T. Tai, I. Kawashima, N. Tada, and T. Fujimori</i> . . . . .	149
<b>16. Tissue Blood Group Carbohydrate Expression and Self: a Hypothesis</b> <i>J. Thurin and B. Bechtel</i> . . . . .	159
<b>17. Immunoblotting Detection of Carbohydrate Epitopes in Glycolipids and Glycoproteins of Tumoral Origin</b> <i>S. Miotti, F. Leoni, S. Canevari, S. Sonnino, and M. I. Colnaghi</i> . . . . .	167
<b>18. Fine Specificity Analysis of Human Monoclonal Antibodies Detecting Gangliosides</b> <i>K. O. Lloyd and K. Furukawa</i> . . . . .	177
<b>19. Glycosphingolipid Expression in Murine T Cells and Macrophages</b> <i>P. F. Mühlradt, J. Müthing, and R. v. Kleist</i> . . . . .	185
<b>20. Activation of T Lymphocytes by Binding of Monoclonal Antibodies to Cell Surface GD3</b> <i>A. N. Houghton, H. Yuasa, P. B. Chapman, and K. Welte</i> . . . . .	197
<b>21. Immunoregulatory Activity of Gangliosides Shed by Melanoma Tumors</b> <i>J. Portoukalian</i> . . . . .	207
<b>22. Tumor Gangliosides: Shedding, Structural Characterization, and Immunosuppressive Activity</b> <i>S. Ladisch</i> . . . . .	217
<b>23. Clinical Evaluation of Monoclonal Antibody Against GD3 Ganglioside in Patients with Metastatic Melanoma</b> <i>A. N. Houghton, D. Bajorin, P. Chapman, J. DiMaggio, H. F. Oettgen, and L. J. Old</i> . . . . .	231

<b>24. Immunological Response to Intrathecal GD3-Ganglioside Antibody Treatment in Cerebrospinal Fluid Melanosis</b> <i>W. G. Dippold, H. Bernhard and K.-H. Meyer zum Büschenfelde</i> . . . . .	239
<b>25. Gangliosides Recognized by Human Monoclonal Antibody: Targets for Immunotherapy of Cancer</b> <i>R. F. Irie and P.J. Chandler</i> . . . . .	247
<b>26. Therapy of Neuroblastoma with GD2 Specific Monoclonal Antibody 3F8</b> <i>D. H. Munn, C. Cordon-Cardo, S. D. J. Yeh, B. H. Kushner, and N.-K. V. Cheung</i> . . . . .	259
<b>27. GM3 Lactone as an Immunogen Associated with Melanoma: Effect of Immunization with GM3 Lactone on Melanoma Growth in vivo</b> <i>T. Dohi, G. A. Nores, H. Oguchi, H. Inufusa, and S. Hakomori</i> . . . . .	273
<b>28. Role of Soluble GM3 Melanoma Antigen in Anti-tumor Immune Responses of Mice</b> <i>Y. Harada, M. Sakatsume, and M. Taniguchi</i> . . . . .	283
<b>29. Immunization of Melanoma Patients with Purified Gangliosides</b> <i>P. O. Livingston, G. Ritter, H. F. Oettgen, and L. J. Old</i> . . . . .	293
<b>30. Development of Melanoma Vaccines: Gangliosides as Immunogens</b> <i>G. Ritter, P. O. Livingston, E. Boosfeld, H. Wiegandt, R. K. Yu, H. F. Oettgen, and L. J. Old</i> . . . . .	301
<b>31. Epitopes on Ganglioside GD2 and its Lactones: Markers for Gliomas and Neuroblastomas</b> <i>K. Bosslet, H. D. Mennel, F. Rodden, B. L. Bauer, F. Wagner, H. H. Sedlacek, and H. Wiegandt</i> . . . . .	315
<b>32. Determination of the Secondary Structures of Glycosphingolipids by NMR Spectroscopy</b> <i>R. K. Yu</i> . . . . .	333
<b>33. Effects of Phorbol Esters, Dimethylsulfoxide, and Gangliosides on the Biosynthesis of Glycolipids by HL-60 Promyelocytic Leukemia Cells</b> <i>X.-J. Xia, S. Ren, A. C. Sartorelli, and R. K. Yu</i> . . . . .	341
<b>34. Summary and Perspectives</b> <i>S. Hakomori</i> . . . . .	355
<b>Index</b> . . . . .	361